Designing and evaluating provider results-based financing for tuberculosis care in Georgia (RBF4TB)
Introduction and Overview
CIF in partnership with Queen Margaret University (UK), London School of Hygiene and Tropical Medicine (UK) and Antwerp Institute of Tropical Medicine (Belgium) is implementing a study “Designing and evaluating provider results-based financing for tuberculosis care in Georgia: understanding costs, mechanisms of effect and impact”. The 48-month research project will assist the Government of Georgia in developing a provider incentive payment scheme for Tuberculosis. It will generate evidence on its effects on adherence and treatment success rates and costs.
The research will seek to answer the following research questions:
(1) What is the impact of provider-focused Results-Based Financing (RBF) on patients, adherence to tuberculosis treatment and treatment outcomes of both Drug-Susceptible (DS) and Multi Drug Resistant (MDR) patients in Georgia?
(2) Is the RBF intervention cost-effective?
(3) How does it work, for whom and in which conditions?
(4) How should RBF be modified to optimize national roll-out for this and possibly other health services?
Project has launched in March 2017 and will run till March 2021.
Organizations involved in the research
The project is funded through the Joint Health Systems Research Initiative, which is jointly funded by the Department of International Development (DFID), the Economic and Social Research Council (ESRC), the Medical Research Council (MRC) and the Wellcome Trust (WT).
The study will be implemented by CIF (Georgia), Queen Margaret University (UK), London School of Hygiene and Tropical Medicine (UK) and Antwerp Institute of Tropical Medicine (Belgium).
Expected Results and Their Application
The beneficiaries of this research will be TB patients, nurses and physicians involved in TB care, health facility managers, policy-makers, community members and the scientific community in Georgia, in the region and globally.
The research will narrow the knowledge gap existing around RBF interventions, such as their application in public/private settings and their cost-effectiveness, the conditions of success and the wider (negative and positive) consequences of the scheme.
The research will also produce methodological innovation regarding the use of realist evaluation alongside cost effectiveness analysis.
National policy-makers will use the evidence produced through this research to reform the financing of primary health schemes in a way that improves efficiency, quality and sustainability of services. Additionally, findings will be beneficial for other LMICs, particularly for those with a similar vertical organization of TB services (most of the former Socialist countries of Eastern and Central Europe and Central Asia) and for countries where private providers play an important role in the provision of TB services.